Logo image of EWTX

EDGEWISE THERAPEUTICS INC (EWTX) Stock Fundamental Analysis

USA - NASDAQ:EWTX - US28036F1057 - Common Stock

22.26 USD
-0.49 (-2.15%)
Last: 11/17/2025, 8:00:02 PM
22.2 USD
-0.06 (-0.27%)
After Hours: 11/17/2025, 8:00:02 PM
Fundamental Rating

3

Overall EWTX gets a fundamental rating of 3 out of 10. We evaluated EWTX against 192 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for EWTX as it has an excellent financial health rating, but there are worries on the profitability. EWTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EWTX had negative earnings in the past year.
EWTX had a negative operating cash flow in the past year.
In the past 5 years EWTX always reported negative net income.
In the past 5 years EWTX always reported negative operating cash flow.
EWTX Yearly Net Income VS EBIT VS OCF VS FCFEWTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

EWTX has a Return On Assets (-24.57%) which is in line with its industry peers.
EWTX has a better Return On Equity (-25.58%) than 62.50% of its industry peers.
Industry RankSector Rank
ROA -24.57%
ROE -25.58%
ROIC N/A
ROA(3y)-25.12%
ROA(5y)-20.69%
ROE(3y)-26.69%
ROE(5y)-21.83%
ROIC(3y)N/A
ROIC(5y)N/A
EWTX Yearly ROA, ROE, ROICEWTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EWTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EWTX Yearly Profit, Operating, Gross MarginsEWTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for EWTX has been increased compared to 1 year ago.
EWTX has more shares outstanding than it did 5 years ago.
There is no outstanding debt for EWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EWTX Yearly Shares OutstandingEWTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
EWTX Yearly Total Debt VS Total AssetsEWTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

EWTX has an Altman-Z score of 58.43. This indicates that EWTX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of EWTX (58.43) is better than 97.92% of its industry peers.
There is no outstanding debt for EWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 58.43
ROIC/WACCN/A
WACCN/A
EWTX Yearly LT Debt VS Equity VS FCFEWTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 28.87 indicates that EWTX has no problem at all paying its short term obligations.
The Current ratio of EWTX (28.87) is better than 96.88% of its industry peers.
EWTX has a Quick Ratio of 28.87. This indicates that EWTX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 28.87, EWTX belongs to the best of the industry, outperforming 96.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 28.87
Quick Ratio 28.87
EWTX Yearly Current Assets VS Current LiabilitesEWTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for EWTX have decreased by -5.33% in the last year.
EPS 1Y (TTM)-5.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 18.62% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-13.43%
EPS Next 2Y-17.83%
EPS Next 3Y-13.31%
EPS Next 5Y18.62%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EWTX Yearly Revenue VS EstimatesEWTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
EWTX Yearly EPS VS EstimatesEWTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EWTX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EWTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EWTX Price Earnings VS Forward Price EarningsEWTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EWTX Per share dataEWTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

EWTX's earnings are expected to decrease with -13.31% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.83%
EPS Next 3Y-13.31%

More info and screens

0

5. Dividend

5.1 Amount

EWTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EDGEWISE THERAPEUTICS INC

NASDAQ:EWTX (11/17/2025, 8:00:02 PM)

After market: 22.2 -0.06 (-0.27%)

22.26

-0.49 (-2.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-02 2026-03-02/amc
Inst Owners94.14%
Inst Owner Change-8.67%
Ins Owners0.53%
Ins Owner Change0.64%
Market Cap2.35B
Revenue(TTM)N/A
Net Income(TTM)-150.70M
Analysts82.11
Price Target36.07 (62.04%)
Short Float %10.25%
Short Ratio10.2
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.75%
Min EPS beat(2)1.73%
Max EPS beat(2)19.77%
EPS beat(4)4
Avg EPS beat(4)6.91%
Min EPS beat(4)1.18%
Max EPS beat(4)19.77%
EPS beat(8)6
Avg EPS beat(8)5.08%
EPS beat(12)10
Avg EPS beat(12)6.23%
EPS beat(16)11
Avg EPS beat(16)3.44%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.55%
PT rev (3m)-11.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.01%
EPS NY rev (1m)0.1%
EPS NY rev (3m)8.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.98
P/tB 3.98
EV/EBITDA N/A
EPS(TTM)-1.58
EYN/A
EPS(NY)-2.01
Fwd EYN/A
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS5.59
TBVpS5.59
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -24.57%
ROE -25.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.12%
ROA(5y)-20.69%
ROE(3y)-26.69%
ROE(5y)-21.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.4%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 28.87
Quick Ratio 28.87
Altman-Z 58.43
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)644.61%
Cap/Depr(5y)457.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.33%
EPS Next Y-13.43%
EPS Next 2Y-17.83%
EPS Next 3Y-13.31%
EPS Next 5Y18.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.72%
EBIT Next 3Y-18.74%
EBIT Next 5Y32.18%
FCF growth 1Y-63.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-86.57%
OCF growth 3YN/A
OCF growth 5YN/A

EDGEWISE THERAPEUTICS INC / EWTX FAQ

What is the fundamental rating for EWTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to EWTX.


Can you provide the valuation status for EDGEWISE THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to EDGEWISE THERAPEUTICS INC (EWTX). This can be considered as Overvalued.


What is the profitability of EWTX stock?

EDGEWISE THERAPEUTICS INC (EWTX) has a profitability rating of 1 / 10.


Can you provide the financial health for EWTX stock?

The financial health rating of EDGEWISE THERAPEUTICS INC (EWTX) is 8 / 10.


What is the expected EPS growth for EDGEWISE THERAPEUTICS INC (EWTX) stock?

The Earnings per Share (EPS) of EDGEWISE THERAPEUTICS INC (EWTX) is expected to decline by -13.43% in the next year.